{
    "id": 17327,
    "fullName": "TP53 del",
    "impact": "deletion",
    "proteinEffect": "loss of function",
    "geneVariantDescriptions": [
        {
            "description": "TP53 del indicates a deletion of the TP53 gene.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 7157,
        "geneSymbol": "TP53",
        "terms": [
            "TP53",
            "BCC7",
            "BMFS5",
            "LFS1",
            "P53",
            "TRP53"
        ]
    },
    "variant": "del",
    "createDate": "01/29/2016",
    "updateDate": "08/29/2017",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 10737,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Kevetrin (thioureidobutyronitrile) treatment resulted in Tp53-independent increase of Cdkn1a expression and apoptosis of ovarian clear cell carcinoma cells harboring TP53 deletion in culture and in cell line xenograft models (Proceedings of the AACR, Vol 58, Apr 2017, abstract # 3221).",
            "molecularProfile": {
                "id": 17613,
                "profileName": "TP53 del"
            },
            "therapy": {
                "id": 2999,
                "therapyName": "thioureidobutyronitrile",
                "synonyms": null
            },
            "indication": {
                "id": 50934,
                "name": "ovarian clear cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 8790,
                    "pubMedId": null,
                    "title": "Kevetrin induces p53-dependent and independent cell cycle arrest and apoptosis in ovarian cancer cell lines representing heterogeneous histologies",
                    "url": "http://www.abstractsonline.com/pp8/#!/4292/presentation/3876"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10682,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, MK-8745 treatment resulted in polyploidy in TP53-null colorectal cancer cells in culture (PMID: 22293494).",
            "molecularProfile": {
                "id": 17613,
                "profileName": "TP53 del"
            },
            "therapy": {
                "id": 5579,
                "therapyName": "TC-A2317",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 8741,
                    "pubMedId": 22293494,
                    "title": "The induction of polyploidy or apoptosis by the Aurora A kinase inhibitor MK8745 is p53-dependent.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22293494"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6070,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Nutlin-3 and cisplatin worked cooperatively to induce apoptosis and decrease growth of ovarian cancer cells with TP53 deletion in culture (PMID: 25964101).",
            "molecularProfile": {
                "id": 17613,
                "profileName": "TP53 del"
            },
            "therapy": {
                "id": 4018,
                "therapyName": "Cisplatin + Nutlin-3",
                "synonyms": null
            },
            "indication": {
                "id": 2394,
                "name": "ovarian cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5272,
                    "pubMedId": 25964101,
                    "title": "Pharmacologically Increasing Mdm2 Inhibits DNA Repair and Cooperates with Genotoxic Agents to Kill p53-Inactivated Ovarian Cancer Cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25964101"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6071,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Nutlin-3 and etoposide worked cooperatively to induce apoptosis and decrease growth of ovarian cancer cells with TP53 deletion in culture (PMID: 25964101).",
            "molecularProfile": {
                "id": 17613,
                "profileName": "TP53 del"
            },
            "therapy": {
                "id": 4017,
                "therapyName": "Etoposide + Nutlin-3",
                "synonyms": null
            },
            "indication": {
                "id": 2394,
                "name": "ovarian cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5272,
                    "pubMedId": 25964101,
                    "title": "Pharmacologically Increasing Mdm2 Inhibits DNA Repair and Cooperates with Genotoxic Agents to Kill p53-Inactivated Ovarian Cancer Cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25964101"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10907,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, sequential administration of Roscovotine (seliciclib) followed by Adriamycin (doxorubicin) synergistically induced apoptosis in TP53-null colorectal cancer cells in culture (PMID: 26826118).",
            "molecularProfile": {
                "id": 17613,
                "profileName": "TP53 del"
            },
            "therapy": {
                "id": 5678,
                "therapyName": "Doxorubicin + Seliciclib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 8919,
                    "pubMedId": 26826118,
                    "title": "Sequential Combination Therapy of CDK Inhibition and Doxorubicin Is Synthetically Lethal in p53-Mutant Triple-Negative Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26826118"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6069,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with Nutlin-3 had little effect on growth of ovarian cancer cells with deletion of TP53 in culture (PMID: 25964101).",
            "molecularProfile": {
                "id": 17613,
                "profileName": "TP53 del"
            },
            "therapy": {
                "id": 1405,
                "therapyName": "Nutlin-3",
                "synonyms": null
            },
            "indication": {
                "id": 2394,
                "name": "ovarian cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 5272,
                    "pubMedId": 25964101,
                    "title": "Pharmacologically Increasing Mdm2 Inhibits DNA Repair and Cooperates with Genotoxic Agents to Kill p53-Inactivated Ovarian Cancer Cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25964101"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16198,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclincal study, Tanespimycin (17-AAG) treatment of mutagen induced colorectal cancer in a genetic mouse model with biallelic loss of TP53 was less effective than treatment of mice bearing a single allele with a TP53 R248Q mutation (PMID: 30107178).",
            "molecularProfile": {
                "id": 17613,
                "profileName": "TP53 del"
            },
            "therapy": {
                "id": 934,
                "therapyName": "Tanespimycin",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 14313,
                    "pubMedId": 30107178,
                    "title": "Therapeutic Ablation of Gain-of-Function Mutant p53 in Colorectal Cancer Inhibits Stat3-Mediated Tumor Growth and Invasion.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30107178"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 6324,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, combination of Erivedge (vismodegib) and Posaconazole demonstrated enhanced inhibition of Hedgehog signaling in mouse basal cell carcinoma cells harboring PTCH1 loss and TP53 deletion in culture (PMID: 26823493).",
            "molecularProfile": {
                "id": 23083,
                "profileName": "PTCH1 loss TP53 del"
            },
            "therapy": {
                "id": 4114,
                "therapyName": "Posaconazole + Vismodegib",
                "synonyms": null
            },
            "indication": {
                "id": 2513,
                "name": "basal cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5515,
                    "pubMedId": 26823493,
                    "title": "Posaconazole, a Second-Generation Triazole Antifungal Drug, Inhibits the Hedgehog Signaling Pathway and Progression of Basal Cell Carcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26823493"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6266,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Posaconazole inhibited tumor growth in allograft models of basal cell carcinoma derived from mice with heterozygous PTCH1 loss and TP53 knockout (PMID: 26823493).",
            "molecularProfile": {
                "id": 23083,
                "profileName": "PTCH1 loss TP53 del"
            },
            "therapy": {
                "id": 4108,
                "therapyName": "Posaconazole",
                "synonyms": null
            },
            "indication": {
                "id": 2513,
                "name": "basal cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5515,
                    "pubMedId": 26823493,
                    "title": "Posaconazole, a Second-Generation Triazole Antifungal Drug, Inhibits the Hedgehog Signaling Pathway and Progression of Basal Cell Carcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26823493"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6323,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, combination of Cyclopamine and Posaconazole demonstrated enhanced inhibition of Hedgehog signaling in mouse basal cell carcinoma cells harboring PTCH1 loss and TP53 deletion in culture (PMID: 26823493).",
            "molecularProfile": {
                "id": 23083,
                "profileName": "PTCH1 loss TP53 del"
            },
            "therapy": {
                "id": 4113,
                "therapyName": "Cyclopamine + Posaconazole",
                "synonyms": null
            },
            "indication": {
                "id": 2513,
                "name": "basal cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5515,
                    "pubMedId": 26823493,
                    "title": "Posaconazole, a Second-Generation Triazole Antifungal Drug, Inhibits the Hedgehog Signaling Pathway and Progression of Basal Cell Carcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26823493"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7044,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with Adavosertib (MK-1775) induced apoptosis of mouse proneural glioblastoma cells lacking TP53 and PTEN and over expressing PDGFB in cell culture (PMID: 27196784).",
            "molecularProfile": {
                "id": 24369,
                "profileName": "PDGFB over exp PTEN del TP53 del"
            },
            "therapy": {
                "id": 822,
                "therapyName": "Adavosertib",
                "synonyms": null
            },
            "indication": {
                "id": 50804,
                "name": "glioblastoma proneural subtype",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6050,
                    "pubMedId": 27196784,
                    "title": "Quantitative Phosphoproteomics Reveals Wee1 Kinase as a Therapeutic Target in a Model of Proneural Glioblastoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27196784"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10882,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, 7RH treatment had no effect on tumor cell apoptosis in KRAS G12V-driven animal models of lung cancer with TP53 knockout background (PMID: 26855149).",
            "molecularProfile": {
                "id": 27818,
                "profileName": "KRAS G12V TP53 del"
            },
            "therapy": {
                "id": 5669,
                "therapyName": "7RH",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 8887,
                    "pubMedId": 26855149,
                    "title": "Combined inhibition of DDR1 and Notch signaling is a therapeutic strategy for KRAS-driven lung adenocarcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26855149"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10883,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, 7RH and LY411575 combination treatment induced apoptosis in KRAS G12V-driven animal models of lung cancer with TP53 knockout background (PMID: 26855149).",
            "molecularProfile": {
                "id": 27818,
                "profileName": "KRAS G12V TP53 del"
            },
            "therapy": {
                "id": 5670,
                "therapyName": "7RH + LY411575",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8887,
                    "pubMedId": 26855149,
                    "title": "Combined inhibition of DDR1 and Notch signaling is a therapeutic strategy for KRAS-driven lung adenocarcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26855149"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11535,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Xalkori (crizotinib) treatment resulted in complete tumor regression in transplant models of TP53-null-luminal breast cancer harboring MET amplification (PMID: 27149990).",
            "molecularProfile": {
                "id": 28118,
                "profileName": "MET amp TP53 del"
            },
            "therapy": {
                "id": 706,
                "therapyName": "Crizotinib",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9604,
                    "pubMedId": 27149990,
                    "title": "Genomic profiling of murine mammary tumors identifies potential personalized drug targets for p53-deficient mammary cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27149990"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11897,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, PKF118-310 inhibited Kdm4a activity and induced apoptosis in TP53-deleted leukemia cells in culture (PMID: 27767379).",
            "molecularProfile": {
                "id": 28336,
                "profileName": "KDM4A pos TP53 del"
            },
            "therapy": {
                "id": 2397,
                "therapyName": "PKF118-310",
                "synonyms": null
            },
            "indication": {
                "id": 1240,
                "name": "leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9770,
                    "pubMedId": 27767379,
                    "title": "Identification and characterization of PKF118-310 as a KDM4A inhibitor.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27767379"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11894,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, PKF118-310 inhibited Kdm4a activity and induced apoptosis in TP53-deleted colon cancer cells (PMID: 27767379).",
            "molecularProfile": {
                "id": 28336,
                "profileName": "KDM4A pos TP53 del"
            },
            "therapy": {
                "id": 2397,
                "therapyName": "PKF118-310",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9770,
                    "pubMedId": 27767379,
                    "title": "Identification and characterization of PKF118-310 as a KDM4A inhibitor.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27767379"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16312,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Rozlytrek (entrectinib) treatment reduced viability of TP53-null mouse adult neuronal stem cells harboring BCAN-NTRK1 in culture, and improved survival and decreased tumor cell proliferation in xenograft models (PMID: 28695888).",
            "molecularProfile": {
                "id": 31590,
                "profileName": "BCAN - NTRK1 TP53 del"
            },
            "therapy": {
                "id": 1455,
                "therapyName": "Entrectinib",
                "synonyms": null
            },
            "indication": {
                "id": 3620,
                "name": "central nervous system cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 14433,
                    "pubMedId": 28695888,
                    "title": "Somatic chromosomal engineering identifies BCAN-NTRK1 as a potent glioma driver and therapeutic target.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28695888"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 17613,
            "profileName": "TP53 del",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 23083,
            "profileName": "PTCH1 loss TP53 del",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 24369,
            "profileName": "PDGFB over exp PTEN del TP53 del",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 27818,
            "profileName": "KRAS G12V TP53 del",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 28118,
            "profileName": "MET amp TP53 del",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 28336,
            "profileName": "KDM4A pos TP53 del",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 31590,
            "profileName": "BCAN - NTRK1 TP53 del",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}